Chmp recommends eu approval of regeneron antibody cocktail to treat and prevent covid-19

Tarrytown, n.y., nov. 11, 2021 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has adopted a positive opinion for the casirivimab and imdevimab antibody cocktail, known as regen-cov® in the u.s. and ronapreve™ in the european union (eu) and other countries.
REGN Ratings Summary
REGN Quant Ranking